Merck to invest Euro 50 mn in German pharma packaging unit

The unit will focus on Merck's brands Glucophage, Concor and Euthyrox to meet increasing patient needs in the areas of diabetes, cardiovascular diseases and thyroid disorders

Merck invests in pharmaceutical packaging building
Merck invests in pharmaceutical packaging building
BS B2B Bureau Darmstadt, Germany
Last Updated : Sep 26 2016 | 3:32 PM IST
Merck, the Germany-based science and technology company, will invest more than Euro 50 million in a state-of-the-art packaging building at its pharmaceutical manufacturing site in Darmstadt, Germany.

“Sustained growth of healthcare needs in the areas of diabetes, cardiovascular diseases and thyroid disorders continues to meet increased patient demand. We are committed to helping to ensure that our medicines are always available to patients who need them. Therefore, we are investing in our manufacturing and supply network across the world to continuously adapt our footprint and capacity while leveraging new technologies to always better serve patients,” said Belen Garijo, member of the executive board of Merck and CEO healthcare, at the cornerstone-laying ceremony on September 21, 2016.

“Darmstadt is our largest site and centre of excellence for oral and solid dosage forms and this new packaging building will be the place to implement state-of-the-art smart packaging technology,” added Thierry Hulot, head of global manufacturing & supply at the biopharma business of Merck.

With its flexible and modern technology, this new centre of excellence will enable the packaging of more than 400 million blisters or 150 million packs annually. It will use energy-saving technologies, and forms part of Merck’s strategy to sustainably secure its leading position in healthcare manufacturing. It is aligned with other investments across Merck’s manufacturing network worldwide and aims to further strengthen the company’s manufacturing footprint and upgrade its services for patients. 

Construction of the 15,000 square meter packaging building is planned to be completed by the end of 2017 and expected to be operational as of mid-2018. 

In Darmstadt, Merck is committed to invest around Euro 1 billion until 2020 and this investment is part of this initiative.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 26 2016 | 3:03 PM IST

Next Story